MX2017008455A - Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida. - Google Patents
Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.Info
- Publication number
- MX2017008455A MX2017008455A MX2017008455A MX2017008455A MX2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A
- Authority
- MX
- Mexico
- Prior art keywords
- implantation
- receptor antagonist
- pregnancy
- luteal phase
- oxytocin receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
- A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere al uso de un antagonista del receptor de oxitocina en hembras que se someten a trasferencia embrionaria como parte de una tecnología de reproducción asistida. En particular, se proporcionan métodos para aumentar la tasa de implantación en curso, aumentar la tasa de embarazos en curso, aumentar la tasa de embarazos clínicos y/o aumentar la tasa de nacidos vivos en un sujeto hembra que se somete a transferencia embrionaria. Específicamente, los antagonistas se liberan en la fase lútea cuando el endometrio es receptivo para la implantación del embrión y/o cuando el embrión ha alcanzado la fase de blastocisto.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199709.8A EP3037101B1 (en) | 2014-12-22 | 2014-12-22 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
US14/643,307 US9579305B2 (en) | 2014-12-22 | 2015-03-10 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
PCT/NL2015/050893 WO2016105190A1 (en) | 2014-12-22 | 2015-12-21 | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017008455A true MX2017008455A (es) | 2018-04-26 |
Family
ID=52338895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017008455A MX2017008455A (es) | 2014-12-22 | 2015-12-21 | Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida. |
Country Status (21)
Country | Link |
---|---|
US (4) | US9579305B2 (es) |
EP (2) | EP3501533A1 (es) |
JP (2) | JP6858130B2 (es) |
KR (1) | KR20170135821A (es) |
CN (2) | CN113940990A (es) |
AU (1) | AU2015367900B2 (es) |
BR (1) | BR112017013521A2 (es) |
CA (1) | CA2971846A1 (es) |
CL (1) | CL2017001640A1 (es) |
EA (1) | EA201791361A1 (es) |
ES (1) | ES2716862T3 (es) |
IL (1) | IL253078B (es) |
MX (1) | MX2017008455A (es) |
MY (1) | MY181349A (es) |
PH (1) | PH12017550030A1 (es) |
PL (1) | PL3037101T3 (es) |
SG (1) | SG11201705175RA (es) |
TW (1) | TWI702043B (es) |
UA (1) | UA125492C2 (es) |
WO (1) | WO2016105190A1 (es) |
ZA (1) | ZA201704958B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2845850A1 (en) | 2013-09-10 | 2015-03-11 | ObsEva S.A. | Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists |
EP2886107A1 (en) | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
UA122210C2 (uk) | 2014-07-02 | 2020-10-12 | Обсева С.А. | Кристалічний о-метилоксим (3z,5s)-5-(гідроксиметил)-1-[(2'-метил-1,1'-біфеніл-4-іл)карбоніл]піролідин-3-oну, корисний у способах лікування станів, пов'язаних з активністю ot-r |
EP3501533A1 (en) | 2014-12-22 | 2019-06-26 | Ferring B.V. | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
AU2017205670B2 (en) | 2016-01-04 | 2021-05-20 | Merck Serono S.A. | L-valinate of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof |
CA3031252A1 (en) * | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
EP4025207A1 (en) | 2019-09-03 | 2022-07-13 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
US20230102503A1 (en) | 2020-02-10 | 2023-03-30 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
CN114292907A (zh) * | 2020-12-15 | 2022-04-08 | 苏州亿康医学检验有限公司 | 用于反复植入失败的生物标志物和诊断与治疗方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
AUPP421298A0 (en) | 1998-06-19 | 1998-07-09 | Fertilitescentrum Ab | Method and medium for in vitro culture of human embryos |
HUP0302632A2 (hu) * | 2001-01-09 | 2003-11-28 | Schering Ag | Antigesztagének alkalmazása gyorsított endometriális érés gátlására meddőségi kezelés alatt |
YU21104A (sh) * | 2001-09-12 | 2006-08-17 | Applied Research Systems Ars Holding N.V. | Upotreba hcg i lh u kontrolisanoj hiperstimulaciji ovarijuma |
EP1480998B1 (en) | 2002-02-27 | 2006-11-22 | Ferring BV | Intermediates and methods for making heptapeptide oxytocin analogues |
UA78058C2 (en) * | 2002-07-05 | 2007-02-15 | Applied Research Systems | Pyrrolidine derivative as oxitocin antagonists |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
FR2849380A1 (fr) * | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
US7111275B2 (en) | 2003-08-28 | 2006-09-19 | International Business Machines Corporation | Electronic circuit design analysis system |
EP1664003A1 (en) | 2003-09-18 | 2006-06-07 | Axys Pharmaceuticals, Inc. | Haloalkyl containing compounds as cysteine protease inhibitors |
MXPA06003158A (es) | 2003-09-22 | 2006-06-05 | Pfizer | Derivados de triazol sustituidos como antagonistas de oxitocina. |
EP1555029A1 (en) | 2004-01-19 | 2005-07-20 | Ferring B.V. | Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension |
KR100985449B1 (ko) * | 2005-05-10 | 2010-10-05 | 페링 인터내셔널 센터 에스 에이 | 옥시톡신 및/또는 바소프레신 길항제의 용도 |
WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
AU2010246918A1 (en) | 2009-05-14 | 2011-12-01 | Adelaide Research & Innovation Pty Ltd | Methods for the collection and maturation of oocytes |
JP6186353B2 (ja) | 2011-07-01 | 2017-08-23 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ヒト卵丘細胞の発生ステージを決定するための方法 |
US10271876B2 (en) | 2011-11-23 | 2019-04-30 | Mezadata Medical Ip Holding Llc | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells |
WO2013181549A2 (en) | 2012-05-31 | 2013-12-05 | Auxogyn, Inc. | In vitro embryo blastocyst prediction methods |
EP2922475A1 (en) | 2012-11-26 | 2015-09-30 | Ferring BV | Method and system for diagnosing uterine contraction levels using image analysis |
EP3501533A1 (en) | 2014-12-22 | 2019-06-26 | Ferring B.V. | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies |
-
2014
- 2014-12-22 EP EP19153560.8A patent/EP3501533A1/en active Pending
- 2014-12-22 EP EP14199709.8A patent/EP3037101B1/en active Active
- 2014-12-22 PL PL14199709T patent/PL3037101T3/pl unknown
- 2014-12-22 ES ES14199709T patent/ES2716862T3/es active Active
-
2015
- 2015-03-10 US US14/643,307 patent/US9579305B2/en active Active
- 2015-12-18 TW TW104142629A patent/TWI702043B/zh active
- 2015-12-21 KR KR1020177020292A patent/KR20170135821A/ko not_active Application Discontinuation
- 2015-12-21 BR BR112017013521-3A patent/BR112017013521A2/pt not_active Application Discontinuation
- 2015-12-21 CN CN202111236155.1A patent/CN113940990A/zh active Pending
- 2015-12-21 CN CN201580076659.8A patent/CN107249618B/zh active Active
- 2015-12-21 CA CA2971846A patent/CA2971846A1/en active Pending
- 2015-12-21 MY MYPI2017702341A patent/MY181349A/en unknown
- 2015-12-21 US US15/538,639 patent/US10688106B2/en active Active
- 2015-12-21 AU AU2015367900A patent/AU2015367900B2/en active Active
- 2015-12-21 WO PCT/NL2015/050893 patent/WO2016105190A1/en active Application Filing
- 2015-12-21 EA EA201791361A patent/EA201791361A1/ru unknown
- 2015-12-21 UA UAA201707648A patent/UA125492C2/uk unknown
- 2015-12-21 JP JP2017551985A patent/JP6858130B2/ja active Active
- 2015-12-21 SG SG11201705175RA patent/SG11201705175RA/en unknown
- 2015-12-21 MX MX2017008455A patent/MX2017008455A/es active IP Right Grant
-
2017
- 2017-01-17 US US15/408,256 patent/US10183029B2/en active Active
- 2017-06-21 IL IL253078A patent/IL253078B/en active IP Right Grant
- 2017-06-21 CL CL2017001640A patent/CL2017001640A1/es unknown
- 2017-06-22 PH PH12017550030A patent/PH12017550030A1/en unknown
- 2017-07-20 ZA ZA201704958A patent/ZA201704958B/en unknown
-
2020
- 2020-05-18 US US16/877,186 patent/US11752157B2/en active Active
-
2021
- 2021-01-08 JP JP2021002022A patent/JP7184935B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017550030A1 (en) | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | |
MX2017001804A (es) | Mioinositol y uno o mas probioticos y sus usos. | |
MX2021008858A (es) | Vitamina b2 para la diabetes gestacional. | |
LT2982352T (lt) | Gimdos kaklelio pesaras, turintis progesterono, skirtas prailgintam, nepertraukiamam ir tolygiam progesterono atpalaidavimui, naudojamas priešlaikinio gimdymo profilaktikai | |
PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
MX2016014913A (es) | Dispositivo y formulacion para el tratamiento topico de dolor que afecta a la zona vulvar del organo genital humano femenino. | |
MX2017001632A (es) | Mioinositol y probioticos, y uso de estos. | |
MY172530A (en) | Method for treating gynecological diseases | |
AR095834A1 (es) | Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica | |
PH12015502160A1 (en) | Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women | |
IL250212A0 (en) | Tungsten salts (vi) for use in the treatment of infertility, to favor normal fertility and reproduction in the female of non-diabetic mammals, as well as to improve the efficiency of assisted reproduction techniques | |
UA85636U (ru) | Способ лечения угрозы преждевременных родов у беременных с многоплодной беременностью препаратом «спаскупрель» | |
TH180281A (th) | การบำบัดของออกซีโตซินรีเซปเตอร์แอนตาโกนิสต์ในระยะหลังไข่ตก สำหรับการฝังตัวและการตั้งครรภ์ในผู้หญิงที่ได้รับเทคโนโลยีที่เกี่ยวกับ การสืบพันธุ์ที่ได้รับการช่วยเหลือ | |
Gracheva | Peculiarities of pregravid preparation of women with non-differentiated connective tissue dysplasia | |
PH12018502440A1 (en) | Angiotensin-1-receptor antagonists | |
UA78016U (ru) | Способ диагностики внутриутробного состояния плода при плацентарной дисфункции в III триместре беременности | |
UA77310U (ru) | Способ оценки готовности организма к родам и состояния плода при доношенной беременности | |
UA75352U (ru) | Способ получения зародышей телят требуемого пола | |
UA105280U (uk) | Спосіб профілактики передчасних пологів при багатоплідній вагітності | |
RU2013121133A (ru) | Способ профилактики задержания последа у коров | |
WO2015008087A3 (en) | Control of uterine contractions | |
UA106165U (uk) | Спосіб лікування фіброзно-кістозної мастопатії у жінок з міомою матки | |
MX2016011801A (es) | Crema de estradiol de dosis baja. | |
UA74691U (ru) | Способ диагностики опухолей молочной железы | |
IN2013MU02732A (es) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |